Last reviewed · How we verify
Travoprost 004% sterile ophthalmic solution
Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Travoprost 004% sterile ophthalmic solution |
|---|---|
| Also known as | Travatan |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F (FP) receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. The 0.004% concentration is optimized for topical ocular delivery to achieve therapeutic effect while minimizing systemic exposure.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: